Bouiller K, et al. - In view of the findings that the vancomycin minimum inhibitory concentration (MIC) affected the outcome of methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia, researchers here assessed the outcomes of patients with MSSA bacteremia, with a vancomycin MIC≥ 1.5 mg/L. In this study, irrespective of the first- and second-line treatment, vancomycin MIC ≥ 1.5 mg/L was not associated with 30-day mortality, but was associated with uncomplicated bacteremia in MSSA bacteremia. A different clonal distribution of S. aureus and a low reproducibility of vancomycin MICs measured by Etest could explain the discrepancy between these results and those of previous studies.